DIN Standards Committee Health Technologies
DIN EN ISO 11239
Health informatics - Identification of medicinal products - Data elements and structures for the unique identification and exchange of regulated information on pharmaceutical dose forms, units of presentation, routes of administration and packaging (ISO 11239:2012); German version EN ISO 11239:2012
Medizinische Informatik - Identifikation von Arzneimitteln - Struktur und kontrollierte Vokabularien zur Identifikation von pharmazeutischen Darreichungsformen, pharmazeutischen Konventionseinheiten, Anwendungsarten und Verpackungen (ISO 11239:2012); Deutsche Fassung EN ISO 11239:2012
Overview
This standard was developed in response to a worldwide demand for internationally harmonized specifications for medicinal products. It is one of five standards which together provide the basis for the unique identification of medicinal products. The group of standards comprises: - ISO 11615, Health informatics - Identification of medicinal products - Data elements and structures for the unique identification and exchange of regulated medicinal product information; - ISO 11616, Health informatics - Identification of medicinal products - Data elements and structures for the unique identification and exchange of regulated pharmaceutical product information; - ISO 11238, Health informatics - Identification of medicinal products - Data elements and structures for the unique identification and exchange of regulated information on substances; - ISO 11239, Health informatics - Identification of medicinal products - Data elements and structures for the unique identification and exchange of regulated information on pharmaceutical dose forms, units of presentation, routes of administration and packaging; - ISO 11240, Health informatics - Identification of medicinal products - Data elements and structures for the unique identification and exchange of units of measurement. The standards for the identification of medicinal products support the activities of medicines regulatory agencies worldwide. These activities include a variety of activities related to development, registration and life cycle management of medicinal products, as well as pharmacovigilance and risk management. To meet the primary objectives of the regulation of medicines and pharmacovigilance, it is necessary to reliably exchange medicinal product information in a robust and reliable manner. The IDMP standards therefore support the following interactions: - regulator to regulator, for example, the European Medicines Agency - U.S. Food and Drug Administration (FDA) or vice versa; - pharmaceutical company to regulator, for example, pharmaceutical company A - Health Canada; - sponsor of clinical trial to regulator, for example, university X - Austrian regulator; - regulator to other stakeholder, for example, Medicines Health Regulatory Agency (MHRA) - National Health System in Great Britain; - regulator to worldwide-maintained data sources, for example, Pharmaceutical and Medical Device Agency (PMDA) and allocation to a new substance identifier. The necessary messaging specifications are included as an integral part of the IDMP standards to secure these interactions. Unique identifiers produced in conformance with the IDMP standards are aimed to support applications where it is necessary to reliably identify and trace the use of medicinal products. There are many terms in use to describe basic concepts in the regulatory, pharmaceutical and healthcare standards development domain for different purposes and in different contexts. The terms and definitions given in this standard are to be applied for the concepts which are required to uniquely identify, characterize and exchange regulated medicinal products and associated information. The terms and definitions adopted in this standard are intended to facilitate the interpretation and application of legal and regulatory requirements but they are without prejudice to any legally binding document. In case of doubt or potential conflict, the terms and definitions contained in legally binding documents prevail. This standard describes the essential elements for the specification, translation and versioning of the specified controlled terms. Also described are recommendations concerning the mapping of terms that are already used by stakeholders to the concepts arising from the implementation of this standard. The high-level concepts defined consist of: pharmaceutical dose form, unit of presentation, route of administration, packaging. The supporting, more mechanical, components are described separately from the high-level clinical concepts. The supporting concepts consist of: terms and codes, translations, versioning, mapping. Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. The committee responsible for this standard is NA 063-07-03 AA "Terminologie" ("Terminology") at DIN.
